Dr. Bellmunt on Challenges With Immunotherapy in Bladder Cancer – OncLive
|
Dr. Bellmunt on Challenges With Immunotherapy in Bladder Cancer
OncLive Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses challenges with immunotherapy in bladder cancer. The challenge is to improve on the 20% of … |
